-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Lyell Immunopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q2 2024.
- Lyell Immunopharma, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$51.5M, a 21.8% increase year-over-year.
- Lyell Immunopharma, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$226M, a 7.62% decline year-over-year.
- Lyell Immunopharma, Inc. annual Operating Income (Loss) for 2023 was -$247M, a 32% decline from 2022.
- Lyell Immunopharma, Inc. annual Operating Income (Loss) for 2022 was -$187M, a 12.9% increase from 2021.
- Lyell Immunopharma, Inc. annual Operating Income (Loss) for 2021 was -$215M, a 1.34% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)